StockData

Lycia Therapeutics, Inc. (LYCA) shareholders

LYCANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$31.35+0.43 (+1.39%)

Close on Nov 18, 2026Market cap –P/E –Yield –

Ownership

Who owns Lycia Therapeutics's shares

Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
12 buys · 0 sales
Net bought $38.52M

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Venrock Healthcare Capital Partners III, L.P.
Joint filing with VHCP Co-Investment Holdings III, LLC (11.90%), Venrock Healthcare Capital Partners EG, L.P. (11.90%) and 6 more
6,850,23711.90%13G (passive)Oct 23, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares ownedLatest filing
Aetna Wun TrombleyPresident and CEO, Director, 10% owner415,255Oct 26, 2026
Steven StabenChief Scientific Officer, 10% owner55,448Oct 26, 2026
Amy BachrodtChief Financial Officer, 10% owner–Oct 26, 2026
Chin Hyok LeeChief Medical Officer, 10% owner–Oct 26, 2026
Sofia TouamiChief Business Officer–Oct 26, 2026
William Jl RieflinDirector89,781Oct 26, 2026
Jane HendersonDirector–Oct 26, 2026
Laurent FischerDirector33,269Oct 26, 2026
Venrock Healthcare Capital Partners III, L.P.10% owner6,858,542Nov 4, 2026
VHCP Management EG, LLC10% owner–Nov 4, 2026
Venrock Healthcare Capital Partners EG, L.P.10% owner–Nov 4, 2026
VHCP Co-Investment Holdings III, LLC10% owner–Nov 4, 2026
Venrock Healthcare Capital Partners XP, L.P.10% owner–Nov 4, 2026
VHCP Management XP, LLC10% owner–Nov 4, 2026
VHCP Management III, LLC10% owner–Nov 4, 2026
Bong Y. Koh10% owner–Nov 4, 2026
Nimish P. Shah10% owner–Nov 4, 2026
Versant Ventures VII GP, L.P.10% owner1,393,882Oct 28, 2026
Versant Vantage II GP, L.P.10% owner–Oct 28, 2026
Versant Vantage II GP-GP, LLC10% owner–Oct 28, 2026
Versant Venture Capital VII, L.P.10% owner–Oct 28, 2026
Versant Vantage II, L.P.10% owner–Oct 28, 2026
Versant Ventures VII GP-GP, LLC10% owner–Oct 28, 2026
LILLY & Co ELI10% owner1,104,558Oct 22, 2026
Carolyn R. Bertozzi10% owner904,821Oct 22, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Venrock Healthcare Capital Partners III, L.P.
10% owner
Nov 2, 2026Buy+8,305$26.95$223.82K6,858,542
Venrock Healthcare Capital Partners III, L.P.
10% owner
Oct 30, 2026Buy+200$26.86$5.37K6,850,237
Venrock Healthcare Capital Partners III, L.P.
10% owner
Oct 30, 2026Buy+8,804$26.27$231.28K6,850,037
Venrock Healthcare Capital Partners III, L.P.
10% owner
Oct 29, 2026Buy+1,000$26.33$26.33K6,841,233
Venrock Healthcare Capital Partners III, L.P.
10% owner
Oct 28, 2026Buy+4,430$25.97$115.05K6,840,233
Venrock Healthcare Capital Partners III, L.P.
10% owner
Oct 28, 2026Buy+10,570$25.23$266.68K6,835,803
Venrock Healthcare Capital Partners III, L.P.
10% owner
Oct 27, 2026Buy+31,067$26.84$833.84K6,825,233
Venrock Healthcare Capital Partners III, L.P.
10% owner
Oct 27, 2026Buy+8,729$25.84$225.56K6,794,166
Versant Ventures VII GP, L.P.
10% owner
Oct 26, 2026Conversion+1,393,882––1,393,882
Versant Ventures VII GP, L.P.
10% owner
Oct 26, 2026Conversion+5,631,425––5,631,425
Venrock Healthcare Capital Partners III, L.P.
10% owner
Oct 26, 2026Buy+8,261$26.97$222.80K6,785,437
Venrock Healthcare Capital Partners III, L.P.
10% owner
Oct 26, 2026Buy+1,944,444$18.00$35.00M6,777,176
Venrock Healthcare Capital Partners III, L.P.
10% owner
Oct 26, 2026Conversion+4,779,793––4,832,732
Venrock Healthcare Capital Partners III, L.P.
10% owner
Oct 23, 2026Buy+28,379$26.11$740.98K52,939
Venrock Healthcare Capital Partners III, L.P.
10% owner
Oct 23, 2026Buy+24,560$25.68$630.70K24,560

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
–
0M shares short
Days to cover
1.0
At 0M shares a day
Change since last report
–
Short volume, 19 days
43.8%
Of volume reported to FINRA

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Lycia Therapeutics's stock actually held short. No settlement fails above the SEC's reporting threshold in the last 90 days.

See a number that looks wrong?